Determination of a clinically effective evobrutinib dose: Exposure–response analyses of a phase II relapsing multiple sclerosis study
Abstract The pharmacometric analysis of the double‐blind, randomized, phase II study (NCT02975349) investigating the safety and efficacy of evobrutinib, explored exposure–response relationships and suitable dosing regimens of evobrutinib for relapsing multiple sclerosis. Population pharmacokinetic (...
Main Authors: | Orestis Papasouliotis, David Mitchell, Pascal Girard, Fernando Dangond, Martin Dyroff |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-12-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.13407 |
Similar Items
-
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants
by: Orestis Papasouliotis, et al.
Published: (2022-12-01) -
EVOBRUTINIB TREATMENT REDUCES THE DAMAGE TO THE CNS AND INCREASES THE NUMBER OF CLASSICAL DENDRITIC CELLS IN EXPERIMENTAL MULTIPLE SCLEROSIS
by: Mari Paz Serrano-Regal, et al.
Published: (2023-10-01) -
Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib
by: Liza Rijvers, et al.
Published: (2022-08-01) -
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial
by: Daniel J. Wallace, et al.
Published: (2023-01-01) -
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
by: Steffen Pfeuffer, et al.
Published: (2022-09-01)